Literature DB >> 1365657

A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action.

G J Marek1, C J McDougle, L H Price, L S Seiden.   

Abstract

Trazodone is an atypical antidepressant drug that is commonly referred to as a serotonin (5-hydroxytryptamine; 5-HT) uptake inhibitor. However, the most potent pharmacological effect of trazodone appears to be antagonist action at 5-HT2/1C receptors. This is in contrast to fluoxetine, for which inhibition of 5-HT uptake is the most potent pharmacological action. The effects of trazodone and fluoxetine on several antidepressant drug screens are mediated by antagonist action at 5-HT2 receptors and inhibition of 5-HT uptake, respectively. While fluoxetine is an effective agent for the treatment of major depression, obsessive-compulsive disorder (OCD) and panic disorder, trazodone does not appear to be effective in the treatment of OCD and panic disorder. In addition, trazodone and fluoxetine differ in humans with respect to their effects on sleep and weight. Taken together, the preclinical and clinical data suggest that trazodone acts as an antidepressant via antagonist action at 5-HT2/1C receptors, while fluoxetine likely acts as an antidepressant via inhibition of 5-HT uptake.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1365657     DOI: 10.1007/bf02245475

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  52 in total

Review 1.  Panic disorder: a treatment update.

Authors:  G D Burrows; T R Norman; F K Judd
Journal:  J Clin Psychiatry       Date:  1991-07       Impact factor: 4.384

2.  Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: electrophysiological studies in the rat central nervous system.

Authors:  P Blier; C De Montigny; A J Azzaro
Journal:  J Pharmacol Exp Ther       Date:  1986-06       Impact factor: 4.030

3.  Trazodone in the treatment of depressed inpatients.

Authors:  G A Trapp; C R Handorf; V Larach
Journal:  Psychopharmacol Bull       Date:  1979-07

Review 4.  The comorbidity factor: establishing the primary diagnosis in patients with mixed symptoms of anxiety and depression.

Authors:  P J Clayton
Journal:  J Clin Psychiatry       Date:  1990-11       Impact factor: 4.384

5.  Two distinct effects of 5-hydroxytryptamine on single cortical neurons.

Authors:  M F Davies; R A Deisz; D A Prince; S J Peroutka
Journal:  Brain Res       Date:  1987-10-13       Impact factor: 3.252

6.  Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain.

Authors:  Y Chaput; C de Montigny; P Blier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-08       Impact factor: 3.000

7.  Sertraline-induced desensitization of the serotonin 5HT-2 receptor transmembrane signaling system.

Authors:  E Sanders-Bush; M Breeding; K Knoth; M Tsutsumi
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist?

Authors:  P Schoeffter; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-06       Impact factor: 3.000

9.  Effects of trazodone treatment on serotonergic function in depressed patients.

Authors:  L H Price; D S Charney; G R Heninger
Journal:  Psychiatry Res       Date:  1988-05       Impact factor: 3.222

10.  A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder.

Authors:  J B Cohn; C Wilcox
Journal:  J Clin Psychiatry       Date:  1985-03       Impact factor: 4.384

View more
  13 in total

1.  Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.

Authors:  F J de Abajo; L A Rodríguez; D Montero
Journal:  BMJ       Date:  1999-10-23

Review 2.  A systematic review of pharmacologic treatments of pain after spinal cord injury.

Authors:  Robert W Teasell; Swati Mehta; Jo-Anne L Aubut; Brianne Foulon; Dalton L Wolfe; Jane T C Hsieh; Andrea F Townson; Christine Short
Journal:  Arch Phys Med Rehabil       Date:  2010-05       Impact factor: 3.966

Review 3.  A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.

Authors:  L L Carpenter; C J McDougle; C N Epperson; L H Price
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

4.  A small molecule screening to detect potential therapeutic targets in human podocytes.

Authors:  Eugen Widmeier; Weizhen Tan; Merlin Airik; Friedhelm Hildebrandt
Journal:  Am J Physiol Renal Physiol       Date:  2016-10-19

5.  Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia.

Authors:  L Parrino; M C Spaggiari; M Boselli; G Di Giovanni; M G Terzano
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

6.  The additive effects of quinine on antidepressant drugs in the forced swimming test in mice.

Authors:  W Y Guo; K G Todd; M Bourin; M Hascoet
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

Review 7.  Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders.

Authors:  M Haria; A Fitton; D McTavish
Journal:  Drugs Aging       Date:  1994-04       Impact factor: 3.923

8.  Additive effects of lithium and antidepressants in the forced swimming test: further evidence for involvement of the serotoninergic system.

Authors:  M K Nixon; M Hascoet; M Bourin; M C Colombel
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

9.  Pain and psychiatry: a critical analysis and pharmacological review.

Authors:  Donatella Marazziti; Francesco Mungai; Laura Vivarelli; Silvio Presta; Bernardo Dell'Osso
Journal:  Clin Pract Epidemiol Ment Health       Date:  2006-11-06

10.  β2-Adrenergic Receptor Activation Suppresses the Rat Phenethylamine Hallucinogen-Induced Head Twitch Response: Hallucinogen-Induced Excitatory Post-synaptic Potentials as a Potential Substrate.

Authors:  Gerard J Marek; Brian P Ramos
Journal:  Front Pharmacol       Date:  2018-02-08       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.